Eli Lilly Clinical Trials: 2,120 Led Studies

Archive historyOct 2022 to Jul 2026

88 recorded changes across Eli Lilly trials

Every status move, completion date shift and enrollment change ComplyRx has recorded across 36 of these trials. One is shown below.

Completion date movePrimary completion moved 30 days earlierNCT06662383 · recorded 21 Jul 2026

Track to read them

+84 more recorded changes · Track a drug to see every change the night it lands

Track orforglipron

Most active programmes

The drugs appearing most often across Eli Lilly's recently active trials. Comparator arms are excluded.

Orforglipron10 trials
Brenipatide8 trials
Eloralintide8 trials
Baricitinib6 trials
Tirzepatide6 trials
Retatrutide5 trials

Upcoming readouts

Next primary completion dates among Eli Lilly's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.

Dec 2026A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose…Phase 2
Dec 2026A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in…Phase 2
Feb 2027ADVANCE: A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)Phase 3
Feb 2027RENEW-Smk-1: A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid RelapsePhase 2
Mar 2027A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adul…Phase 2
May 2027A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps…Phase 3

Top therapeutic areas

Conditions studied most often across Eli Lilly's recently active trials.

Obesity19 trials
Overweight15 trials
Diabetes Mellitus, Type 24 trials
Neoplasm Metastasis4 trials
Ulcerative Colitis3 trials
Type 2 Diabetes3 trials

Eli Lilly trials

The 50 most significant of Eli Lilly's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.

Trial	Phase	Stability	Status	Enrollment	Est. readout
A Study of LY3971297 in Healthy ParticipantsNCT06148272LY3971297	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	225 est.	Aug 2026
Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach AcidNCT06916143LY4100511	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	48 est.	Aug 2026
A Study of Food Effect on Tersolisib (LY4064809) in Healthy ParticipantsNCT07662798Tersolisib	Phase 1	Not yet scored	OngoingRecruiting	60 est.	Sept 2026
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)NCT06297603Retatrutide	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	320 est.	Oct 2026
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)NCT04088396Baricitinib	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	58 est.	Oct 2026
A Study of LY4268989 (MORF 057) in Healthy ParticipantsNCT07707375LY4268989	Phase 1	Not yet scored	OngoingNot yet recruiting	50 est.	Oct 2026
A Study of Eloralintide (LY3841136) in Healthy ParticipantsNCT07701083Eloralintide	Phase 1	Not yet scored	OngoingNot yet recruiting	58 est.	Oct 2026
TRIUMPH-5A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityNCT06662383Retatrutide	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	800 est.	Nov 2026
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal InsulinNCT07215312LY3938577	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	100 est.	Nov 2026
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or TirzepatideNCT06897475LY3457263	Phase 2	Locked · track to reveal	OngoingRecruiting	240 est.	Dec 2026
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With CancerNCT07169851LY3537021	Phase 2	Locked · track to reveal	OngoingRecruiting	204 est.	Dec 2026
PIKASSO-01A Study of LOXO-783 in Patients With Breast Cancer/Other Solid TumorsNCT05307705LOXO-783	Phase 1	Locked · track to reveal	OngoingRecruiting	260 est.	Dec 2026
A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise HealthyNCT07225556LY4167586	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	84 est.	Dec 2026
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes MellitusNCT06982859Retatrutide	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	95 est.	Dec 2026
ADVANCEA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)NCT06672549Orforglipron	Phase 3	Locked · track to reveal	OngoingRecruiting	125 est.	Feb 2027
RENEW-Smk-1A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid RelapseNCT07223840Brenipatide	Phase 2	Locked · track to reveal	OngoingRecruiting	222 est.	Feb 2027
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following RadiotherapyNCT06413706Abemaciclib	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	45 est.	Feb 2027
A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or ObesityNCT07476118Brenipatide	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	150 est.	Feb 2027
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 DiabetesNCT07215559Macupatide	Phase 2	Locked · track to reveal	OngoingRecruiting	200 est.	Mar 2027
A Study of LY4584180 in Adult Participants With Previously Treated Blood CancersNCT07226843LY4584180	Phase 1	Locked · track to reveal	OngoingRecruiting	460 est.	Apr 2027
BAF_FRontier-1A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )NCT07101328LY4152199 - IV	Phase 1	Locked · track to reveal	OngoingRecruiting	215 est.	Apr 2027
OA07A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis PainNCT07641517LY4065967	Phase 2	Not yet scored	OngoingNot yet recruiting	150 est.	Apr 2027
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)NCT06338995LY3650150	Phase 3	Locked · track to reveal	OngoingRecruiting	510 est.	May 2027
A Study of LY4005130 in Adult Participants With Non-Segmental VitiligoNCT07533019LY4005130	Phase 2	Locked · track to reveal	OngoingRecruiting	60 est.	May 2027
CAMPFIREA Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With CancerNCT05999994Ramucirumab	Phase 2	Locked · track to reveal	OngoingRecruiting	105 est.	May 2027
TOPAZ-UCLY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:NCT07186101LY4268989	Phase 2	Locked · track to reveal	OngoingRecruiting	252 est.	May 2027
NEXUS-01A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsNCT06465069LY4052031	Phase 1	Locked · track to reveal	OngoingRecruiting	420 est.	May 2027
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)NCT07533006LY4005130	Phase 2	Locked · track to reveal	OngoingRecruiting	60 est.	Jun 2027
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's DiseaseNCT07483099LY4395089	Phase 2	Locked · track to reveal	OngoingRecruiting	60 est.	Jun 2027
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's DiseaseNCT07483073Mirikizumab - Intravenous (IV)	Phase 2	Locked · track to reveal	OngoingRecruiting	60 est.	Jun 2027
RENEW-IBS-CA Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)NCT07545772LY3537031	Phase 2	Locked · track to reveal	OngoingRecruiting	342 est.	Jul 2027
A Study of LY3439539 in Participants With Alzheimer's DiseaseNCT07598370LY3439539	Phase 1	Locked · track to reveal	OngoingRecruiting	30 est.	Aug 2027
A Study of Eloralintide (LY3841136) in Participants With Overweight or ObesityNCT07665879Eloralintide	Phase 1	Not yet scored	OngoingRecruiting	115 est.	Aug 2027
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightNCT06143956LY3305677	Phase 2	Locked · track to reveal	OngoingRecruiting	1,481 est.	Sept 2027
RENEW-IBS-DA Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)NCT07545759LY3537031	Phase 2	Locked · track to reveal	OngoingRecruiting	531 est.	Sept 2027
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)NCT06439277Tirzepatide	Phase 3	Locked · track to reveal	OngoingRecruiting	300 est.	Oct 2027
BRUIN-CLL-314A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)NCT05254743Pirtobrutinib	Phase 3	Locked · track to reveal	OngoingRecruiting	737 est.	Oct 2027
SUNRAY-01A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerNCT06119581LY3537982	Phase 3	Locked · track to reveal	OngoingRecruiting	1,264 est.	Nov 2027
RENEW-Scz-1A Study of Brenipatide in Adult Participants With SchizophreniaNCT07410507Brenipatide	Phase 2	Locked · track to reveal	OngoingRecruiting	450 est.	Nov 2027
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)NCT07286175Brenipatide	Phase 2	Locked · track to reveal	OngoingRecruiting	400 est.	Nov 2027
A Study of LY3971297 in Participants With Heart FailureNCT07547540LY3971297	Phase 1	Locked · track to reveal	OngoingNot yet recruiting	90 est.	Nov 2027
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)NCT06739122Dulaglutide	Phase 3	Locked · track to reveal	OngoingRecruiting	55 est.	Dec 2027
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related ComorbiditiesNCT06672939Orforglipron	Phase 3	Locked · track to reveal	OngoingRecruiting	150 est.	Dec 2027
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative ColitisNCT06598943Eltrekibart	Phase 2	Locked · track to reveal	OngoingRecruiting	140 est.	Dec 2027
ENLIGHTEN-2A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 DiabetesNCT07282600Eloralintide	Phase 3	Locked · track to reveal	OngoingRecruiting	1,035 est.	Jan 2028
RENEW-MDD-1A Study of Brenipatide in Adult Participants With Major Depressive DisorderNCT07412756Brenipatide	Phase 3	Locked · track to reveal	OngoingRecruiting	1,000 est.	Feb 2028
A Study of LY4178256 in Healthy ParticipantsNCT07698210LY4178256	Phase 1	Not yet scored	OngoingNot yet recruiting	88 est.	Feb 2028
ENLIGHTEN-1A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 DiabetesNCT07321886Eloralintide	Phase 3	Locked · track to reveal	OngoingRecruiting	1,980 est.	Mar 2028
RESTRAIN-SUIA Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or OverweightNCT07202884Orforglipron	Phase 3	Locked · track to reveal	OngoingRecruiting	1,000 est.	Mar 2028
ENLIGHTEN-3A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT07369011Eloralintide	Phase 3	Locked · track to reveal	OngoingRecruiting	800 est.	Mar 2028

View all trials2,120

A Study of LY3971297 in Healthy Participants

Phase 1Active, not recruitingNCT06148272 ↗

Primary completion: Aug 2026; estimated
Enrollment: 225; estimated
Start: Dec 2023; Eli Lilly and Company

Conditions

Healthy
Obesity
Hypertension

Interventions

LY3971297
Placebo
LY3971297 IV

Brief summary

The purpose of this study is to measure side effects of LY3971297 injection administered under the skin in healthy participants and obese participants with high blood pressure (BP). Blood tests will be performed to check how much LY3971297 gets into the bloodstream and how long it takes the body to eliminate it. This…

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Dec 2025

Completion date move · 4

Enrollment change · 1

Status change · 1

Track Eli Lilly drugs to see every change the night it lands.

Track orforglipron

Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid

Phase 1Active, not recruitingNCT06916143 ↗

Primary completion: Aug 2026; estimated
Enrollment: 48; estimated
Start: Apr 2025; Eli Lilly and Company

Conditions

Healthy Participants

Interventions

LY4100511
Rabeprazole

Brief summary

The main purpose of this study is to compare the bioavailability of 3 different formulations of LY4100511 and if the use of a proton pump inhibitor (PPI) alters the bioavailability of the 3 different formulations.

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 May 2026

Completion date move · 2

Status change · 1

Track Eli Lilly drugs to see every change the night it lands.

Track orforglipron

Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

Phase 3Active, not recruitingNCT06297603 ↗

Primary completion: Oct 2026; estimated
Enrollment: 320; estimated
Start: Mar 2024; Eli Lilly and Company

Conditions

Type 2 Diabetes

Interventions

Retatrutide
Placebo

Brief summary

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucose cotransporter-2…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Dec 2025

Status change · 2

Completion date move · 1

Track Eli Lilly drugs to see every change the night it lands.

Track orforglipron

A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

Phase 3Active, not recruitingNCT04088396 ↗

Primary completion: Oct 2026; estimated
Enrollment: 58; estimated
Start: Feb 2020; Eli Lilly and Company

Conditions

Systemic Juvenile Idiopathic Arthritis

Interventions

Baricitinib
Tocilizumab

Brief summary

The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with systemic juvenile idiopathic arthritis (sJIA). Participants are assigned to 1 of 2 cohorts. In cohort 1, participants will receive baricitinib or tocilizumab reference. In…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Feb 2026

Completion date move · 3

Enrollment change · 1

Track Eli Lilly drugs to see every change the night it lands.

Track orforglipron

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

Phase 2RecruitingNCT07169851 ↗

Primary completion: Dec 2026; estimated
Enrollment: 204; estimated
Start: Nov 2025; Eli Lilly and Company

Conditions

Nausea
Vomiting
Drug-Related Side Effects and Adverse Reactions
Neoplasms

Interventions

LY3537021
Placebo
Standard of Care Antiemetic Therapies
Background Chemotherapy

Brief summary

The purpose of this study is to check how well LY35327021 works and how safe it is for controlling nausea and vomiting caused by chemotherapy. Participants who join this study will be in it until all parts are finished, which could take about 2 months.

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 May 2026

Completion date move · 1

Status change · 1

Track Eli Lilly drugs to see every change the night it lands.

Track orforglipron

PIKASSO-01: A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

Phase 1RecruitingNCT05307705 ↗

Primary completion: Dec 2026; estimated
Enrollment: 260; estimated
Start: May 2022; Eli Lilly and Company

Conditions

Breast Cancer

Interventions

LOXO-783
Fulvestrant
Imlunestrant
Abemaciclib
Anastrozole, Exemestane, or Letrozole
Paclitaxel

Brief summary

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid tumors that have a change in a particular gene (known as the PIK3CA gene). Participation could last up to 36 months (3 years) and possibly longer if…

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Feb 2026

Enrollment change · 3

Completion date move · 2

Status change · 1

Track Eli Lilly drugs to see every change the night it lands.

Track orforglipron

A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy

Phase 1Active, not recruitingNCT07225556 ↗

Primary completion: Dec 2026; estimated
Enrollment: 84; estimated
Start: Nov 2025; Eli Lilly and Company

Conditions

Overweight
Obesity

Interventions

LY4167586
Placebo
LY4167586

Brief summary

The purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration.…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Jan 2026

Status change · 1

Track Eli Lilly drugs to see every change the night it lands.

Track orforglipron

A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

Phase 2Active, not recruitingNCT06413706 ↗

Primary completion: Feb 2027; estimated
Enrollment: 45; estimated
Start: Oct 2024; Eli Lilly and Company

Conditions

Glioma

Interventions

Abemaciclib
Temozolomide

Brief summary

The purpose of this study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy. Your participation could last approximately 11 months and possibly longer depending upon how you and your tumor respond.

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Mar 2026

Status change · 2

Completion date move · 1

Track Eli Lilly drugs to see every change the night it lands.

Track orforglipron

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Phase 2RecruitingNCT07215559 ↗

Primary completion: Mar 2027; estimated
Enrollment: 200; estimated
Start: Oct 2025; Eli Lilly and Company

Conditions

Obesity
Overweight
Diabetes Mellitus, Type 2

Interventions

Macupatide
Eloralintide
Macupatide Placebo
Eloralintide Placebo

Brief summary

The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Dec 2025

Status change · 1

Track Eli Lilly drugs to see every change the night it lands.

Track orforglipron

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

Phase 1RecruitingNCT07226843 ↗

Primary completion: Apr 2027; estimated
Enrollment: 460; estimated
Start: Apr 2026; Eli Lilly and Company

Conditions

Lymphoma, Non-Hodgkin's
Lymphoma, Diffuse Large B-Cell
Follicular Lymphoma

Interventions

LY4584180
Rituximab

Brief summary

The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Jun 2026

Enrollment change · 1

Completion date move · 1

Status change · 1

Track Eli Lilly drugs to see every change the night it lands.

Track orforglipron

BAF_FRontier-1: A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

Phase 1RecruitingNCT07101328 ↗

Primary completion: Apr 2027; estimated
Enrollment: 215; estimated
Start: May 2026; Eli Lilly and Company

Conditions

Lymphoma, Non-Hodgkin
B-cell Lymphoma
Lymphoma, Large B-Cell, Diffuse
Lymphoma, Follicular
Lymphoma, B-cell Marginal Zone
Waldenstrom Macroglobulinemia
Lymphoma, Mantle Cell

Interventions

LY4152199 - IV

Brief summary

The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the option to continue taking LY4152199 until the study ends.

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Jan 2026

Enrollment change · 1

Track Eli Lilly drugs to see every change the night it lands.

Track orforglipron

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

Phase 3RecruitingNCT06338995 ↗

Primary completion: May 2027; estimated
Enrollment: 510; estimated
Start: Apr 2024; Eli Lilly and Company

Conditions

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Interventions

LY3650150
Placebo
Standard therapy for INCS

Brief summary

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months.

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Nov 2025

Completion date move · 2

Track Eli Lilly drugs to see every change the night it lands.

Track orforglipron

CAMPFIRE: A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

Phase 2RecruitingNCT05999994 ↗

Primary completion: May 2027; estimated
Enrollment: 105; estimated
Start: Jan 2020; Eli Lilly and Company

Conditions

Neoplasms
Child
Adolescent

Interventions

Ramucirumab
Cyclophosphamide
Vinorelbine
Gemcitabine
Docetaxel
Abemaciclib
Irinotecan
Temozolomide

Brief summary

The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug/disease-specific research goals and activities to test them. New studies will be added…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Oct 2024

Completion date move · 1

Track Eli Lilly drugs to see every change the night it lands.

Track orforglipron

TOPAZ-UC: LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

Phase 2RecruitingNCT07186101 ↗

Primary completion: May 2027; estimated
Enrollment: 252; estimated
Start: Nov 2025; Eli Lilly and Company

Conditions

Ulcerative Colitis

Interventions

LY4268989
Mirikizumab
LY4268989 Placebo

Brief summary

The main purpose of the study is to evaluate the effectiveness and safety of LY4268989 when given with mirikizumab compared to mirikizumab alone in adult participants with moderately to severely active ulcerative colitis (UC). Study participation will last approximately 118 weeks, including 104 weeks of treatment and…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Dec 2025

Status change · 1

Track Eli Lilly drugs to see every change the night it lands.

Track orforglipron

NEXUS-01: A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Phase 1RecruitingNCT06465069 ↗

Primary completion: May 2027; estimated
Enrollment: 420; estimated
Start: Jul 2024; Eli Lilly and Company

Conditions

Metastatic Solid Tumor
Recurrent Solid Tumor
Advanced Solid Tumor
Urinary Bladder Neoplasm
Triple Negative Breast Cancer
Non-small Cell Lung Cancer
Esophageal Cancer
Pancreatic Cancer

Interventions

LY4052031

Brief summary

The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Jul 2025

Status change · 2

Enrollment change · 1

Track Eli Lilly drugs to see every change the night it lands.

Track orforglipron

A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

Phase 2RecruitingNCT07483099 ↗

Primary completion: Jun 2027; estimated
Enrollment: 60; estimated
Start: May 2026; Eli Lilly and Company

Conditions

Crohn Disease

Interventions

LY4395089
Mirikizumab - Intravenous (IV)
Mirikizumab - Subcutaneous (SC)

Brief summary

The main purpose of this study is to see how the safety and efficacy of a farnesoid X receptor (FXR) agonist (LY4395089), given together with mirikizumab compares with mirikizumab (alone) in adults with moderately to severely active Crohn's disease (CD). This study is part of the IIBD master protocol and will last…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Jun 2026

Status change · 1

Track Eli Lilly drugs to see every change the night it lands.

Track orforglipron

A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

Phase 2RecruitingNCT07483073 ↗

Primary completion: Jun 2027; estimated
Enrollment: 60; estimated
Start: May 2026; Eli Lilly and Company

Conditions

Colitis, Ulcerative
Crohn Disease

Interventions

Mirikizumab - Intravenous (IV)
Mirikizumab - Subcutaneous (SC)
LY4395089

Brief summary

Study IIBD is a master protocol that will support a collection of individual sub studies that share key design components. Participants will be assigned to the appropriate study prior to randomization to a treatment group. The studies aim to evaluate the efficacy and safety of new treatments in adults with moderately…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Jun 2026

Status change · 1

Track Eli Lilly drugs to see every change the night it lands.

Track orforglipron

RENEW-IBS-C: A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)

Phase 2RecruitingNCT07545772 ↗

Primary completion: Jul 2027; estimated
Enrollment: 342; estimated
Start: Apr 2026; Eli Lilly and Company

Conditions

Irritable Bowel Syndrome
Constipation

Interventions

LY3537031
Placebo

Brief summary

The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Constipation (IBS-C). The study drug will be administered subcutaneously (SC) (under the skin) when compared with placebo. The…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Jun 2026

Status change · 1

Track Eli Lilly drugs to see every change the night it lands.

Track orforglipron

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Phase 2RecruitingNCT06143956 ↗

Primary completion: Sept 2027; estimated
Enrollment: 1,481; estimated
Start: Nov 2023; Eli Lilly and Company

Conditions

Obesity
Overweight

Interventions

LY3305677
LY3841136
Tirzepatide
LY3549492
LY3532226
Placebo
Placebo

Brief summary

The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled…

Full record on ClinicalTrials.gov ↗

Change timeline

11 recorded · latest 1 Jun 2026

Completion date move · 5

Enrollment change · 5

Status change · 1

Track Eli Lilly drugs to see every change the night it lands.

Track orforglipron

RENEW-IBS-D: A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)

Phase 2RecruitingNCT07545759 ↗

Primary completion: Sept 2027; estimated
Enrollment: 531; estimated
Start: May 2026; Eli Lilly and Company

Conditions

Irritable Bowel Syndrome
Diarrhea

Interventions

LY3537031
Placebo

Brief summary

The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated, what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Diarrhea (IBS-D). The study drug will be administered subcutaneously (SC) (under the skin) when compared with placebo. The…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Jun 2026

Status change · 1

Track Eli Lilly drugs to see every change the night it lands.

Track orforglipron

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

Phase 3RecruitingNCT06439277 ↗

Primary completion: Oct 2027; estimated
Enrollment: 300; estimated
Start: Jun 2024; Eli Lilly and Company

Conditions

Obesity
Weight Gain

Interventions

Tirzepatide
Placebo

Brief summary

The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may include up to 23…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Sept 2025

Completion date move · 1

Status change · 1

Track Eli Lilly drugs to see every change the night it lands.

Track orforglipron

BRUIN-CLL-314: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Phase 3RecruitingNCT05254743 ↗

Primary completion: Oct 2027; estimated
Enrollment: 737; estimated
Start: Jul 2022; Loxo Oncology, Inc.

Conditions

Chronic Lymphocytic Leukemia
Leukemia, Lymphocytic
Leukemia, B-cell
Small Lymphocytic Lymphoma

Interventions

Pirtobrutinib
Ibrutinib

Brief summary

The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part 2 of this study evaluates pirtobrutinib monotherapy in treatment-naïve…

Full record on ClinicalTrials.gov ↗

Change timeline

7 recorded · latest 1 Sept 2025

Status change · 3

Completion date move · 3

Enrollment change · 1

Track Eli Lilly drugs to see every change the night it lands.

Track orforglipron

SUNRAY-01: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Phase 3RecruitingNCT06119581 ↗

Primary completion: Nov 2027; estimated
Enrollment: 1,264; estimated
Start: Dec 2023; Eli Lilly and Company

Conditions

Carcinoma, Non-Small-Cell Lung
Neoplasm Metastasis

Interventions

LY3537982
Pembrolizumab
Placebo
Cisplatin
Carboplatin
Pemetrexed

Brief summary

The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Apr 2026

Completion date move · 2

Enrollment change · 1

Status change · 1

Track Eli Lilly drugs to see every change the night it lands.

Track orforglipron

A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

Phase 3RecruitingNCT06672939 ↗

Primary completion: Dec 2027; estimated
Enrollment: 150; estimated
Start: Nov 2024; Eli Lilly and Company

Conditions

Obesity
Overweight

Interventions

Orforglipron
Placebo

Brief summary

The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus Placebo in adolescent participants with obesity, or overweight with related comorbidities. Participation in the study will last…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Jun 2026

Enrollment change · 1

Completion date move · 1

Status change · 1

Track Eli Lilly drugs to see every change the night it lands.

Track orforglipron

ENLIGHTEN-1: A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

Phase 3RecruitingNCT07321886 ↗

Primary completion: Mar 2028; estimated
Enrollment: 1,980; estimated
Start: Feb 2026; Eli Lilly and Company

Conditions

Obesity
Overweight

Interventions

Eloralintide
Placebo

Brief summary

The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants with prediabetes…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Mar 2026

Status change · 1

Track Eli Lilly drugs to see every change the night it lands.

Track orforglipron

ENLIGHTEN-3: A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Phase 3RecruitingNCT07369011 ↗

Primary completion: Mar 2028; estimated
Enrollment: 800; estimated
Start: Feb 2026; Eli Lilly and Company

Conditions

Sleep Apnea, Obstructive
Obesity
Overweight

Interventions

Eloralintide
Placebo

Brief summary

The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2. Study YSA1 will include participants who are unable or…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Mar 2026

Status change · 1

Track Eli Lilly drugs to see every change the night it lands.

Track orforglipron